Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000731639 | SCV000859483 | uncertain significance | not provided | 2018-01-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000731639 | SCV001055101 | likely benign | not provided | 2025-01-20 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000731639 | SCV001825205 | likely benign | not provided | 2019-06-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002535230 | SCV003591012 | likely benign | Inborn genetic diseases | 2022-01-28 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Mayo Clinic Laboratories, |
RCV000731639 | SCV005407938 | uncertain significance | not provided | 2023-06-14 | criteria provided, single submitter | clinical testing | BS1, PVS1_moderate |
Natera, |
RCV001273290 | SCV001456163 | uncertain significance | Bartter syndrome | 2019-10-28 | no assertion criteria provided | clinical testing |